Effect of colchicine and aspirin given together in patients with moderate COVID-19
K Sunil Naik, Niranjan Andhalkar, Sohal Pendse
Contemporary Clinical Trials Communications, doi:10.1016/j.conctc.2023.101070
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Declaration of interests ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The study has been funded by ROMEG therapeutics LLC n but there is no financial interest to disclose related to trial results and manuscript writing/reviewing/publishing. J o u r n a l P r e -p r o o f
References
Arif, Aggarwal, Salicylic Acid (Aspirin)
Bester, Matshailwe, Pretorius, Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8, Cytokine,
doi:10.1016/j.cyto.2018.01.007Bianconiv, Violi, Fallarino, Pignatelli, Sahebkara et al., Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19?, Drugs,
doi:10.1007/s40265-020-01365-1Cao, Wang, Wen, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, New England Journal of Medicine,
doi:10.1056/NEJMoa2001282Chandwani, Shuter, Lopinavir/ritonavir in the treatment of HIV-1 infection: a review, Ther Clin Risk Manag,
doi:10.2147/tcrm.s3285Chow, Khanna, Kethireddy, Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission
Cui, Chen, Li, Liu, Wang, Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, J ThrombHaemost,
doi:10.1111/jth.14830Deftereos, Giannopoulos, Vrachatisda, Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.13136Giannis, Ziogasia, Gianni, Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past, J Clin Virol,
doi:10.1016/j.jcv.2020.104362Godino, Scotti, Maugeri, Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence, International Journal of Cardiology,
doi:10.1016/j.ijcard.2020.09.064Healio, FDA approves ticagrelor-aspirin DAPT to reduce MI, stroke in CAD
J O U R N A L P R E, -p r o o f
J O U R N A L P R E, -p r o o f
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial. medRxiv,
doi:10.1101/2020.08.06.20169573Marotta, FDA: Center for Drug Evaluation and Research; Labelling of Aspirin. Food and Drug Administration
Sriram, Insel Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets, Physiological Reviews
Tardif, Kouz, Waters, Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction, N Engl J Med,
doi:10.1056/NEJMoa1912388Tay, Poh, Rénia, Macary, Ng, The trinity of COVID-19:immunity, inflammation and intervention, Nature Reviews Immunology,
doi:10.1038/s41577-020-0311-8
